MX2017006083A - Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma. - Google Patents

Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.

Info

Publication number
MX2017006083A
MX2017006083A MX2017006083A MX2017006083A MX2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A MX 2017006083 A MX2017006083 A MX 2017006083A
Authority
MX
Mexico
Prior art keywords
tizoxanide
prodrugs
analogue
salt
compositions
Prior art date
Application number
MX2017006083A
Other languages
English (en)
Inventor
Rossignol Jean-Francois
Stachulski Andrew
Original Assignee
Romark Laboratories Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories Lc filed Critical Romark Laboratories Lc
Publication of MX2017006083A publication Critical patent/MX2017006083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen profármacos de tizoxanida, un análogo o sal de la misma. Los profármacos tienen una porción éster que comprende una porción de aminoácido, e incrementan la biodisponibilidad de la tizoxanida, un análogo o sal de la misma. También se describen composiciones y métodos para el tratamiento de una infección intracelular por protozoarios, una infección vírica o un cáncer.
MX2017006083A 2014-11-11 2015-11-11 Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma. MX2017006083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462078384P 2014-11-11 2014-11-11
PCT/US2015/060084 WO2016077420A1 (en) 2014-11-11 2015-11-11 Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof

Publications (1)

Publication Number Publication Date
MX2017006083A true MX2017006083A (es) 2017-11-08

Family

ID=55954973

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006083A MX2017006083A (es) 2014-11-11 2015-11-11 Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.

Country Status (15)

Country Link
US (3) US10100023B2 (es)
EP (1) EP3217795A4 (es)
JP (1) JP6633092B2 (es)
KR (1) KR20170081228A (es)
CN (1) CN107105660A (es)
AU (1) AU2015346413B2 (es)
BR (1) BR112017009651A2 (es)
CA (1) CA2967333A1 (es)
CO (1) CO2017005038A2 (es)
EA (1) EA201790847A1 (es)
IL (1) IL252153A0 (es)
MX (1) MX2017006083A (es)
TW (1) TW201619142A (es)
WO (1) WO2016077420A1 (es)
ZA (1) ZA201703507B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017009651A2 (pt) * 2014-11-11 2017-12-19 Romark Laboratories Lc composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
ES2810303T3 (es) 2016-03-31 2021-03-08 Romark Laboratories Lc Compuestos de tiazolida para tratar infecciones virales
SG10202004425XA (en) 2016-04-11 2020-06-29 Genfit Methods of treatment for cholestatic and fibrotic diseases
WO2017178174A1 (en) * 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
WO2017223491A1 (en) * 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
CN114599365A (zh) * 2019-08-22 2022-06-07 内布拉斯加大学董事会 前药及其制剂
US20230140290A1 (en) * 2020-01-26 2023-05-04 The Board Of Regents Of The University Of Texas Sy Salicylamide derivatives and related methods of making
EP4182304A1 (en) 2020-07-20 2023-05-24 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
EP4199923A1 (en) 2020-08-24 2023-06-28 Romark Laboratories, L.C. Use of thiazolides against coronaviruses
GB202017724D0 (en) 2020-11-10 2020-12-23 Univ Liverpool Pharmaceutically active compound formulations
CN114044761B (zh) * 2021-02-24 2022-05-17 成都贝诺科成生物科技有限公司 一种新的硝基噻唑衍生物及其应用
WO2023040990A1 (zh) * 2021-09-15 2023-03-23 南京强新生物医药有限公司 治疗冠状病毒感染的新联用药物、药物组合物及其用途
WO2023077711A1 (zh) * 2021-11-03 2023-05-11 南方科技大学 预防***癌的药剂的筛选方法及硝唑尼特在制药中的应用
CN114134195B (zh) * 2021-11-03 2024-06-11 南方科技大学 预防***癌的药剂的筛选方法、硝唑尼特在制药中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
IL155799A (en) * 1997-05-07 2004-08-31 Romark Lab Lc Pharmaceutical preparations of thizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US20050171169A1 (en) 2004-02-02 2005-08-04 Rossignol Jean F. Combination chemotherapy for helminth infections
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
JP2008538362A (ja) 2005-04-12 2008-10-23 ロマーク ラボラトリーズ エル．シー． タンパク質の成熟の遮断を介して疾患を処置するための方法、タンパク質ジスルフィドイソメラーゼなどの分子シャペロンの機能を阻害する、またはグリコシル化を妨害する化合物、それらを含む薬学的組成物、および治療剤を同定するためのスクリーニング方法
AU2007204963B2 (en) 2006-01-09 2012-09-27 Romark Laboratories, L.C. Viral hepatitis treatment
CA2695517C (en) * 2007-08-03 2016-09-20 J. Edward Semple Alkylsulfonyl-substituted thiazolide compounds
HUE049501T2 (hu) 2009-02-13 2020-09-28 Romark Laboratories Lc Nitazoxanidot tartalmazó szabályozott felszabadulású gyógyszerkészítmény
KR101760956B1 (ko) 2009-05-12 2017-07-24 로마크 레버러토리즈, 엘.씨. 할로알킬 헤테로아릴 벤즈아미드 화합물
JP5932640B2 (ja) 2009-06-26 2016-06-08 ロマーク ラボラトリーズ エル．シー． インフルエンザを治療するための化合物および方法
US9333193B2 (en) 2010-09-20 2016-05-10 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
WO2012058378A1 (en) 2010-10-29 2012-05-03 Romark Laboratories L.C. Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses
WO2012061190A1 (en) * 2010-11-01 2012-05-10 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
DK2709453T3 (da) 2011-05-16 2020-01-20 Romark Laboratories Lc Anvendelse af thiazolid-forbindelser til forebyggelse og behandling af virussygdomme, cancer og sygdomme forårsaget af intracellulære infektioner
EP3006431B1 (en) 2013-07-04 2019-01-30 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Tizoxanide carbamate and pharmaceutical use thereof
BR112017009651A2 (pt) * 2014-11-11 2017-12-19 Romark Laboratories Lc composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.

Also Published As

Publication number Publication date
AU2015346413A1 (en) 2017-05-25
ZA201703507B (en) 2019-07-31
EA201790847A1 (ru) 2017-11-30
CO2017005038A2 (es) 2017-09-20
BR112017009651A2 (pt) 2017-12-19
TW201619142A (zh) 2016-06-01
JP6633092B2 (ja) 2020-01-22
CA2967333A1 (en) 2016-05-19
EP3217795A1 (en) 2017-09-20
AU2015346413B2 (en) 2019-08-29
KR20170081228A (ko) 2017-07-11
US10358428B2 (en) 2019-07-23
WO2016077420A1 (en) 2016-05-19
US10100023B2 (en) 2018-10-16
EP3217795A4 (en) 2018-08-22
JP2017537977A (ja) 2017-12-21
CN107105660A (zh) 2017-08-29
US20170334868A1 (en) 2017-11-23
US10577337B2 (en) 2020-03-03
IL252153A0 (en) 2017-07-31
US20190276417A1 (en) 2019-09-12
US20190040026A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
MX2017006083A (es) Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
MX2024004386A (es) Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso.
EP3490987A4 (en) NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION.
EP4275747A3 (en) Therapeutic applications of cpf1-based genome editing
EP3356521A4 (en) METHOD AND COMPOSITIONS FOR RNA-TREATED TREATMENT OF HIV INFECTIONS
EP3302709A4 (en) METHODS AND COMPOSITIONS RNA-GUIDED TREATMENT OF HIV INFECTIONS
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
GB2541571A (en) Pharmaceutical compositions
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
EP3474863A4 (en) PHOSPHORAMIDATE FOR TREATING THE HEPATITIS C VIRUS
IL253243A0 (en) Combined preparations for the treatment of cancer or infection
EP3641829A4 (en) INTERFERON PRODRUG FOR TREATMENT OF CANCER
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EP3280422A4 (en) Compositions and methods for the treatment of hbv infection
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX2018015410A (es) Esteres de oxaborol y sus usos.
EP3317290A4 (en) COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION
EP3528629A4 (en) SOIL TREATMENT
ZA201703467B (en) Methods of treating ocular conditions
MX2018005872A (es) Profarmacos de acido nucleico.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EP3294052A4 (en) METHODS OF TREATING CULTIVATED PLANTS
EP3448377A4 (en) METHODS FOR THE TREATMENT OF AN INFECTION
EP3148538A4 (en) Cenicriviroc for the treatment of hiv-2 infection
FR3021871B1 (fr) Composition a base d'anthostema senegalense utilisee comme medicament contre le sida